Invivoscribe Marketing, Author at Invivoscribe - Page 4 of 6

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 141 blog entries.

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Invivoscribe Marketing2021-02-15T19:48:14-08:00May 6th, 2020|2020 Publications, Publications|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Invivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

Invivoscribe Marketing2021-02-11T21:53:32-08:00April 1st, 2020|2020 Publications, Publications|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

Invivoscribe Marketing2021-02-11T21:56:18-08:00March 1st, 2020|2020 Publications, Publications|

Clinical Utility of NGS in Lymphoid Malignancies

Invivoscribe Marketing2022-05-25T03:00:59-07:00February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Invivoscribe Marketing2021-02-11T21:58:45-08:00February 6th, 2020|2020 Publications, Publications|

Monitoring minimal residual disease in the bone marrow using next generation sequencing

Invivoscribe Marketing2021-02-11T22:00:56-08:00January 17th, 2020|2020 Publications, Publications|

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

Invivoscribe Marketing2021-02-11T23:36:10-08:00November 13th, 2019|2019 Publications, Publications|

AMP 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 3 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 2 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 1 of 4

Invivoscribe Marketing2022-05-25T03:01:00-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

Invivoscribe Marketing2021-02-11T23:40:44-08:00October 15th, 2019|2019 Publications, Publications|

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

Invivoscribe Marketing2021-02-11T23:43:09-08:00October 1st, 2019|2019 Publications, Publications|

NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking

Invivoscribe Marketing2019-09-23T22:05:58-07:00August 26th, 2019|Product Releases|

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA

Invivoscribe Marketing2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases|

Invivoscribe – EHA 2019: Part 3 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Invivoscribe – EHA 2019: Part 2 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Invivoscribe – EHA 2019: Part 1 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Invivoscribe Marketing2021-02-15T20:01:10-08:00June 6th, 2019|2019 Publications, Publications|

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 1st, 2019|2019 Videos, Featured Videos, Videos|

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

Invivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases|

AMP Global 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:01:01-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|